eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

  • Novel lipid nanoparticles for mRNA delivery will enhance thermostability, biodegradability and safety and pave the way for new off-the-shelf therapies

eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...